Clinical trial · Interventional
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
NCT04823377CI-TRIAL-00098029PACT-01active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sequential comparative prospective interventional study evaluating the impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care. Comparison between a first period, period (A), of care as usual and a second period, period (B), of systematic and iterative use of a device for optimizing the decision to continue an anti-cancer treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Optimization of the medical decision | Other | — | UNRESOLVED |
| Usual care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Period A: Usual management
- description
- Period of end-of-life care as usual
- interventionNames
- Other: Usual care
- type
- OTHER
- label
- Period B: Process of optimization of the medical decision
- description
- Period of systematic and iterative use of a device for optimizing the decision to continue an anti-cancer treatment.
- interventionNames
- Other: Optimization of the medical decision
Primary outcomes (1)
- measure
- Percentage of patients receiving systemic anticancer treatment in their last days of life
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically or cytologically proven non-small-cell lung carcinoma (NSCLC) including NSCLC with oncogene addiction. 2. Stage IV or IIB/IIIC non irradiable (8th classification TNM, UICC 2015) 3. Patient having completed at least one line of chemotherapy in the context of metastatic disease (or in the context of locoregional disease if the last chemotherapy was less than 6 months ago). 4. ECOG Performance Status ≥ 2. 5. Age ≥ 18. 6. Written informed consent. 7. Patient capable, according to the investigator, to comply with the requirements of the study. Exclusion Criteria: 1. Small Cell Lung Cancer (including mixed forms). 2. Patient with NSCLC for whom a decision has already been made to permanently discontinue all systemic cancer treatment. 3. Impossible follow up for geographical, social or psychological reason. 4. Inability to answer a questionnaire (language or neurological barrier). 5. Patient under guardianship. 6. Patient being treated in a therapeutic trial. 7. Patient not covered by social security. -
References
Publications (0)
Data not yet available
No reference posted for this study.